Endeavor BioMedicines

Our passion for making a difference in people’s lives extends far beyond our walls. We recently had the opportunity to sponsor Vidya Navaratnam, an ENV-101 clinical investigator, in her efforts to run and raise money for the Institute for Respiratory Health through HBF Run for a Reason. Thank you, Vidya, for all you do to impact people’s lives. 

#InTheNews: After presenting new data from our Phase 2a #clinicaltrial of ENV-101, investigator Toby Maher, M.D., Ph.D., Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine of the University of Southern California discussed the findings with Healio.    In this article, hear Dr. Maher’s perspective on the tremendous need for idiopathic pulmonary fibrosis (#IPF) treatments that do more than slow the decline of lung function and why #pulmonologists are keeping a close eye on Endeavor’s ENV-101: https://bit.ly/3VrSNvr    #biotechnews #science #lungdisease 

#InTheNews: Last month at the American Thoracic Society 2024 International Conference, we presented findings from a phase 2a trial that potentially bring us one step closer to disrupting disease and restoring hope for patients with idiopathic pulmonary fibrosis (#IPF). In this Fierce Biotech article, Nick Taylor describes the phase 2a study findings and how they could impact those living with the disease: https://bit.ly/3KaEhly #ATS2024 #biotechnews #science #clinicaltrials #investors

It’s been an inspiring few days at the American Thoracic Society 2024 International Conference discussing the latest innovations in respiratory health, including the new Phase 2a clinical trial results for our lead investigational candidate, ENV-101, in patients with idiopathic pulmonary fibrosis (IPF). Explore our science here: https://bit.ly/4dFg6Jp     #pulmonaryfibrosis #biotechnews #clinicaltrials 

#NEWS: Today Endeavor BioMedicines announced new results from a Phase 2a clinical trial of our lead investigational candidate, ENV-101, in patients with idiopathic pulmonary fibrosis (IPF). The results were presented for the first time today during a late-breaking oral session at the American Thoracic Society International Conference (#ATS2024). Read more here: https://bit.ly/3V4Lkm1   #pulmonaryfibrosis #biotechnews #clinicaltrials  

The American Thoracic Society 2024 International Conference showcases the latest advances and discoveries in respiratory science. We’re excited to be here to share ours - especially in our hometown!    If you’re attending #ATS2024, please join us to hear about the exciting things our team is working on to potentially address unmet needs in idiopathic #pulmonaryfibrosis. Find us at Booth CT7 or at Session A-18 and learn more about us here: https://bit.ly/4dFg6Jp 

Our recent announcement that we raised $132.5 million in an oversubscribed Series C financing is a crucial step in our mission to develop transformational medicines that may restore hope for patients with intractable diseases.   Innovation and the potential to change treatment expectations are made possible by the support of our #investors. Read more about what we mean by Disrupting Disease, Restoring Hope and last month’s #SeriesC financing announcement in this BioPharma Dive article: https://bit.ly/3Ud6YD4   #biotechnews #biotech #fundraising #venturecapital #oncology #lungdiseases 

At Endeavor, our mission is clear: We're committed to advancing therapies with the potential to transform patient outcomes. With a focus on fibrotic #lungdisease and #cancer, we're dedicated to delivering transformational clinical benefits for patients. Learn more: https://bit.ly/49MdUxj  #ILD #IPF #oncology

#ICYMI: Last month we announced that we raised $132.5 million in an oversubscribed #SeriesC financing to advance our pipeline of potential therapies for fibrotic lung diseases and oncology. We are thankful for the support of our investors, board, #biotech community and the entire Endeavor BioMedicines team.     In this BioSpace article, get more details about what this financing means for the future of our pipeline and our goal to restore hope for patients with life-threatening diseases: https://bit.ly/4aVqAmo    #biotechnews #fundraising #venturecapital #oncology #lungdiseases

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: John Hood on Endeavor BioMedicines' $132.5M series C and hedgehog inhibition for IPF. He describes the fundraising environment in biotech and the phase 2 data in IPF that Endeavor unveiled in January and enabled this week's raise. Full video: https://lnkd.in/g8mHpV3Y BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent